Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagnostics for cancer, has announced today that the first patient has been medicated in a Phase I clinical trial of GL-ONC1 combined with
chemoradiotherapy in patients with locoregionally advanced head and neck cancers.
The primary breast tumour had been resected three years previously and adjuvant
chemoradiotherapy had been administered at the time.
2) Immunohistochemistry is mandatory for diagnosis, and ideal treatment includes radical surgery and
chemoradiotherapy.
Patients frequently are unable to afford the daily transportation costs imposed by concurrent
chemoradiotherapy programs.
Focusing on treatment strategies like chemotherapy, concurrent
chemoradiotherapy, and sequential
chemoradiotherapy, an international group of oncologists and surgeons also discuss biologic and targeted therapies, radiation therapy, the role of human papillomavirus (HPV) infections in oropharynx cancer, nuclear imaging, advances in nasopharyngeal and thyroid cancers, new surgical techniques including robotic and minimally invasive surgery, and the evaluation and treatment of dysphagia and aspiration.
The chapter on Stage III: Definitive
Chemoradiotherapy reviews the optimization of combined radiotherapy and chemotherapy with a good discussion on trials using the sequential and concurrent approach, the optimal regimens to be used, and the influence of co-morbidities on outcome.
Patients who receive combined
chemoradiotherapy have an increased median survival time compared with patients who receive either stenting or brachytherapy alone.
Malone, of the Southern Illinois School of Medicine, Springfield has suggested that imaging tests conducted six to eight weeks after patients complete
chemoradiotherapy for head and neck cancer may help identify patients who will respond to treatment and those who will require surgical follow-up.
The largest trial to evaluate the role of
chemoradiotherapy as adjuvant treatment was the US Intergroup 0116.
Current treatment options include surgery, radiation therapy and/or concurrent
chemoradiotherapy.
The articles on gastrointestinal surgery address such issues as bariatric surgery, neoadjuvant
chemoradiotherapy for pancreatic cancer, neoplasms of the pancreas, stomal tumors, imaging, laparascopic surgery and treatment for rectal tumors.
Patients with stage III non-small cell lung cancer did not live longer when researchers added AE-941 (Neovastat), a shark cartilage extract, to standard
chemoradiotherapy in a 53-site phase III trial presented at the annual meeting of the American Society of Clinical Oncology.
